South Korea
· Delayed Price · Currency is KRW SCM Lifescience Statistics
Total Valuation
SCM Lifescience has a market cap or net worth of KRW 39.87 billion. The enterprise value is 41.65 billion.
| Market Cap | 39.87B |
| Enterprise Value | 41.65B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SCM Lifescience has 20.47 million shares outstanding. The number of shares has increased by 37.71% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 20.47M |
| Shares Change (YoY) | +37.71% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 17.03% |
| Owned by Institutions (%) | n/a |
| Float | 16.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.86 |
| PB Ratio | 3.38 |
| P/TBV Ratio | 3.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.66 |
| EV / Sales | 46.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.17 |
Financial Position
The company has a current ratio of 1.27, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.27 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -66.14 |
Financial Efficiency
Return on equity (ROE) is -79.38% and return on invested capital (ROIC) is -30.91%.
| Return on Equity (ROE) | -79.38% |
| Return on Assets (ROA) | -28.21% |
| Return on Capital (ROIC) | -30.91% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | 1.08 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.43% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -21.43% |
| 50-Day Moving Average | 1,998.94 |
| 200-Day Moving Average | 2,462.99 |
| Relative Strength Index (RSI) | 50.17 |
| Average Volume (20 Days) | 157,653 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SCM Lifescience had revenue of KRW 889.44 million and -15.65 billion in losses. Loss per share was -763.98.
| Revenue | 889.44M |
| Gross Profit | 412.04M |
| Operating Income | -11.69B |
| Pretax Income | -15.65B |
| Net Income | -15.65B |
| EBITDA | -10.89B |
| EBIT | -11.69B |
| Loss Per Share | -763.98 |
Balance Sheet
The company has 2.28 billion in cash and 4.06 billion in debt, giving a net cash position of -1.78 billion or -86.78 per share.
| Cash & Cash Equivalents | 2.28B |
| Total Debt | 4.06B |
| Net Cash | -1.78B |
| Net Cash Per Share | -86.78 |
| Equity (Book Value) | 11.79B |
| Book Value Per Share | 576.07 |
| Working Capital | 764.19M |
Cash Flow
In the last 12 months, operating cash flow was -11.27 billion and capital expenditures -1.85 billion, giving a free cash flow of -13.12 billion.
| Operating Cash Flow | -11.27B |
| Capital Expenditures | -1.85B |
| Free Cash Flow | -13.12B |
| FCF Per Share | -641.01 |
Margins
| Gross Margin | 46.33% |
| Operating Margin | -1,313.92% |
| Pretax Margin | -1,759.22% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SCM Lifescience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.71% |
| Shareholder Yield | -37.71% |
| Earnings Yield | -39.22% |
| FCF Yield | -32.91% |
Stock Splits
The last stock split was on September 15, 2023. It was a forward split with a ratio of 1.2.
| Last Split Date | Sep 15, 2023 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
SCM Lifescience has an Altman Z-Score of -10.56. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.56 |
| Piotroski F-Score | n/a |